🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against superbug strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating worldwide, with data suggesting in excess of 82 million instances annually. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices currently available.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Receive Authorization

One new antibiotic, alternatively called a brand name, was authorized by the US FDA in December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in close succession. This drug, which is additionally indicated for urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This approval represents a significant shift in the therapy of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

Based on findings published in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The study included nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Clinicians directly involved have expressed positive views. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for managing the epidemic. This is viewed as vital to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.